EGFR (L792H/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.L792H;p.L858R
Components
p.L792Hp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.5% | 0.6% | 96.49 |
| 2 | Mobocertinib | 98.6% | 1.4% | 97.22 |
| 3 | Erlotinib | 95.1% | 4.9% | 99.75 |
| 4 | Lazertinib | 94.8% | 5.2% | 97.47 |
| 5 | Neratinib | 94.5% | 5.5% | 93.18 |
| 6 | Vandetanib | 88.8% | 11.2% | 95.74 |
| 7 | Pacritinib | 65.5% | 34.5% | 88.64 |
| 8 | Pralsetinib | 58.8% | 41.3% | 93.43 |
| 9 | Pirtobrutinib | 14.0% | 86.0% | 99.49 |
| 10 | Gilteritinib | 13.6% | 86.4% | 88.97 |
| 11 | Alpelisib | 12.3% | 87.7% | 97.22 |
| 12 | Defactinib | 10.8% | 89.2% | 92.68 |
| 13 | Deucravacitinib | 9.0% | 91.0% | 98.99 |
| 14 | Tepotinib | 8.8% | 91.2% | 99.75 |
| 15 | Repotrectinib | 7.8% | 92.2% | 84.21 |
| 16 | Avapritinib | 7.0% | 93.0% | 97.73 |
| 17 | Gedatolisib | 6.2% | 93.8% | 99.75 |
| 18 | Zanubrutinib | 4.3% | 95.7% | 98.24 |
| 19 | Entrectinib | 4.3% | 95.7% | 93.69 |
| 20 | Selpercatinib | 4.1% | 95.9% | 96.72 |
| 21 | Darovasertib | 4.0% | 96.0% | 96.99 |
| 22 | Sunitinib | 2.7% | 97.3% | 91.73 |
| 23 | Erdafitinib | 2.4% | 97.6% | 95.71 |
| 24 | Pemigatinib | 2.1% | 97.9% | 98.23 |
| 25 | Tucatinib | 1.8% | 98.2% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.5% | 98.4% | +1.0% |
| Mobocertinib | 98.6% | 100.0% | -1.4% |
| Erlotinib | 95.1% | 99.4% | -4.3% |
| Lazertinib | 94.8% | 100.0% | -5.2% |
| Neratinib | 94.5% | 100.0% | -5.5% |
| Vandetanib | 88.8% | 99.3% | -10.5% |
| Pacritinib | 65.5% | — | — |
| Pralsetinib | 58.8% | 99.1% | -40.4% |
| Pirtobrutinib | 14.0% | — | — |
| Gilteritinib | 13.6% | 91.0% | -77.4% |
| Alpelisib | 12.3% | — | — |
| Defactinib | 10.8% | 94.6% | -83.8% |
| Deucravacitinib | 9.0% | — | — |
| Tepotinib | 8.8% | — | — |
| Repotrectinib | 7.8% | — | — |
| Avapritinib | 7.0% | — | — |
| Gedatolisib | 6.2% | — | — |
| Zanubrutinib | 4.3% | 88.2% | -83.9% |
| Entrectinib | 4.3% | — | — |
| Selpercatinib | 4.1% | — | — |
| Darovasertib | 4.0% | — | — |
| Sunitinib | 2.7% | — | — |
| Erdafitinib | 2.4% | — | — |
| Pemigatinib | 2.1% | — | — |
| Tucatinib | 1.8% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.6ms